ALLERGY TREATMENT DRUGS MARKET ANALYSIS

Allergy Treatment Drugs MarketSize and Trends

Global Allergy Treatment Drugs Market – Dynamics

Rising incidence of allergic conjunctivitis and rhinitis is expected to propel growth of the global allergy treatment drugs market over the forecast period. For instance, according to the article published in the Asia Pacific Association of Allergy, Asthma and Clinical Immunology, in April 2019, simple allergic conjunctivitis affects around 10% to 30% of the population globally. Moreover, according to the National Health Interview Survey, 2018, around 19.2 million adults and 5.2 million children were diagnosed with allergic rhinitis in the U.S. in 2017.

Moreover, various mergers, agreements, and acquisitions among key players are expected to drive the growth of allergy treatment drugs market over the forecast period. For instance, in July 2018, Glenmark Specialty S.A., a division of Glenmark Pharmaceuticals Ltd. (Glenmark), entered into an exclusive licensing agreement with Seqirus Pty. Ltd., to commercialize Ryaltris in Australia and New Zealand. Ryaltris is a nasal spray used for the treatment of symptoms associated with seasonal allergic rhinitis. Furthermore, rising product approvals by the regulatory authorities are expected to propel the growth of allergy treatment market. For instance, in December 2019, Glenmark Pharmaceuticals Ltd., announced that Seqirus Pty. Ltd., received marketing approval from the Therapeutic Goods Administration (TGA), Australia.